Investors

2018 News

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
Aug 02, 2018CTI BioPharma Reports Second Quarter 2018 Financial Results
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE, Aug. 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the second quarter and six months ended June 30, 2018. In July 2018, CTI BioPharma announced the continuation without modification of the PAC203 Phase 2 study following a planned interim review by an Independent Data Monitoring Committee. The Company also announced a pacritinib program update following a ... 
Printer Friendly Version
Jul 26, 2018CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018
SEATTLE, July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results on Thursday, August 2, 2018, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows: Thur... 
Printer Friendly Version
Jul 18, 2018CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
- Regulatory path to include Phase 3 trial expected to begin in 2019 - - Company to request additional meeting with FDA following second interim review of PAC203 - SEATTLE, July 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it recently conducted a Type B meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate pacritinib. The purpose of the meeting was to discuss the regulatory pathway for pacritinib. Based on FDA feedback,... 
Printer Friendly Version
Jul 09, 2018Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
PIXUVRI® plus rituximab did not show a statistically significant improvement in progression-free survival compared to gemcitabine plus rituximab SEATTLE, July 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) and Servier today announced that the pivotal Phase III trial (PIX306) evaluating PIXUVRI® (pixantrone) combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) did not meet its primary endpoint of... 
Printer Friendly Version
Jul 02, 2018CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
SEATTLE, July 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned interim data review by the Independent Data Monitoring Committee (IDMC) of PAC203, the study will continue without modification and that a second interim review will be conducted in the third quarter of 2018. The IDMC did not identify any drug- or dose-related safety concerns and specifically did not identify any concerns about cardiac or bleeding events. The PAC203 study is evalu... 
Printer Friendly Version
Jun 14, 2018CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference
SEATTLE, June 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the JMP Securities 2018 Life Sciences Conference in New York, NY on Thursday, June 21, 2018 at 1:00 PM ET. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma Corp. CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition,... 
Printer Friendly Version
Jun 06, 2018CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference
SEATTLE, June 6, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host one-on-one meetings. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma Corp. CTI BioPharma Corp. is a biopharmaceutical company fo... 
Printer Friendly Version
May 21, 2018CTI Biopharma Corporate Presentation
... 
Printer Friendly Version
May 03, 2018CTI BioPharma Reports First Quarter 2018 Financial Results
-Management to Host Conference Call/ Webcast Today at 4:30 p.m. Eastern Time- SEATTLE, May 3, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the first quarter ended March 31, 2018. In March 2018, results from the Phase 3 PERSIST-2 clinical trial of pacritinib were published online in JAMA Oncology. The randomized, international, multicenter study compared the efficacy and safety of pacritinib at two dose levels, compared with best available th... 
Printer Friendly Version
Apr 26, 2018CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018
SEATTLE, April 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2018 financial results on Thursday, May 3, 2018, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows: Thursda... 
Printer Friendly Version
Mar 09, 2018CTI BioPharma to Present at Upcoming Investor Conferences
SEATTLE, March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present and host one-on-one meetings at the following investor conferences during the month of March: 30th Annual Roth Conference in Laguna Niguel, CA Date: Monday, March 12, 2018 Time: 8:30PM ET / 5:30PM PT Oppenheimer 28th Annual Healthcare Conference in New York, NY Date: Tuesday, March 20, 2018 Time: 10:55AM ET / 7:55AM PT 17th Annual Needham Health... 
Printer Friendly Version
Mar 09, 2018CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
SEATTLE, March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that results from the Phase 3 PERSIST-2 clinical trial of pacritinib (an investigational JAK2 inhibitor) have been published online in JAMA Oncology. The randomized, international, multicenter study compared the efficacy and safety of pacritinib at two dose levels, compared with best available therapy (BAT), which included ruxolitinib (a JAK1/JAK2 inhibitor), in patients with myelofibrosis a... 
Printer Friendly Version
Mar 07, 2018CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results
-Management to Host Conference Call/ Webcast Today at 4:30 p.m. Eastern Time- SEATTLE, March 7, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2017. Clinical / Regulatory In July 2017, the first patient was enrolled in PAC203, a Phase 2 clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy and/or have thrombocytopenia, to evaluate t... 
Printer Friendly Version
Feb 28, 2018CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018
SEATTLE, Feb. 28, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2017 financial results on Wednesday, March 7, 2018, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as fo... 
Printer Friendly Version
Feb 14, 2018CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
SEATTLE, Feb. 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY on Thursday, February 15, 2018 at 2:30 PM ET and host one-on-one meetings. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma Corp. CTI BioPharma Corp. is a biopharm... 
Printer Friendly Version
Feb 13, 2018CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
SEATTLE, Feb. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. ("CTI BioPharma") (NASDAQ: CTIC) today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, the underwriters exercised in full their option to purchase 3,000,000 additional shares of common stock at the public offering price, less the underwriting discount. The expected proceeds to CTI BioPha... 
Printer Friendly Version
Feb 09, 2018CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock
SEATTLE, Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPharma has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less the underwriting discount. Proceeds to CTI BioPharma from the offeri... 
Printer Friendly Version
Feb 05, 2018CTI BioPharma Announces Launch of Follow-On Offering
SEATTLE, Feb. 5, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced the launch of a proposed underwritten public offering of shares of its common stock. In addition, CTI BioPharma expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. The Company intends to use the net proceeds of the offering to complete the PAC203 clinical trial, complete the review of the pacritinib MAA by the EMA, conduct additional research c... 
Printer Friendly Version
Jan 25, 2018CTI BioPharma Provides Corporate and European Regulatory Update
- CTI BioPharma reincorporated in State of Delaware, delisted from Borsa Italiana MTA Exchange - Extension granted by CHMP of the EMA for response to Day 120 List of Questions for the MAA for pacritinib SEATTLE, Jan. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that it has been reincorporated in the State of Delaware following a Special Meeting of Shareholders, triggering an automatic delisting of CTI's common stock from the Borsa Italiana M... 
Printer Friendly Version
Jan 18, 2018CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®
SEATTLE, Jan. 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it expects to receive a $10 million milestone payment in February, 2018 from Teva Pharmaceutical Industries Ltd.  related to the achievement of a milestone for U.S. Food and Drug Administration approval of TRISENOX® (arsenic trioxide) for first line treatment of acute promyelocytic leukemia. The milestone will be paid pursuant to an acquisition agreement for TRISENOX previously entered into with... 
Printer Friendly Version